20 articles
Mesoblast licenses CAR technology to make its stem cell therapies smarter at finding inflamed tissue, targeting IBD and autoimmune disease.
A naturally occurring stem cell type called Muse cells shows early promise in homing to damaged tissue, differentiating widely, and avoiding immune rejection.
Beijing's 301 Hospital begins recruiting adults 50+ for the world's largest stem cell antiaging clinical trial using an already-approved therapy.
A rare stress-resilient cell type may solve the biggest failure in stem cell therapy: most injected cells never reach damaged tissue.
A rare stress-enduring stem cell subpopulation called Muse cells could solve regenerative medicine's biggest failures and slow tissue aging.
Deramiocel slowed upper limb decline by 54% and preserved heart function in boys with Duchenne muscular dystrophy in a landmark phase III trial.
Heartseed's iPSC-derived heart cell therapy enters Phase I/II trial for dilated cardiomyopathy, with first patient data cleared by safety board.
CellProthera's ProtheraCytes targets heart repair post-myocardial infarction, aiming to prevent heart failure before damage becomes irreversible.
BioCardia's bone marrow cell therapy shows lasting gains in exercise tolerance and dramatic angina reduction in chronic heart disease patients.
Astellas reports encouraging early-stage results for a stem cell-derived treatment targeting age-related eye disease, though data remains limited.
XellSmart's XS411 transplants lab-grown dopamine neurons into Parkinson's brains, showing early motor gains and no adverse events.
A dual therapy clearing senescent cells and restoring stem cell function dramatically extended mouse lifespan in a new preclinical study.
Engineered heart muscle patches from stem cells thickened weakened heart walls and improved pumping ability in a small human trial.
Aspen Neuroscience's stem cell therapy restored dopamine neurons in Parkinson's patients, adding ~2 hours of controlled movement daily.
Chinese biotech begins multicenter trial of stem cell therapy showing promising early results for Parkinson's motor symptoms and quality of life.
RTX001, a regenerative macrophage cell therapy, reduced liver inflammation and fibrosis in mouse models ahead of Phase I/II trial results.
Ossium Health is banking donor bone marrow for on-demand transplant, targeting immune aging as a future healthspan intervention.
Aspen's personalized iPSC cell therapy shows meaningful motor and quality-of-life gains in first 8 Parkinson's patients at 12 months.
RBI's Wnt-activated stem cells injected directly into the brain show early promise reducing tau and amyloid markers in Phase 1.
A Cleveland Clinic hematologist explains how exploding CAR-T options and new drug classes are reshaping myeloma care and patient decisions.
